What's Happening?
OrganaBio, LLC, a cell therapy contract development and manufacturing organization based in Miami, has acquired the operating assets of Excellos Inc., a San Diego-based company. This acquisition aims to
create a bicoastal cell therapy service provider, enhancing OrganaBio's capabilities in manufacturing, PBMC isolation, and cryopreservation services. The acquisition includes Excellos' downtown San Diego facility, which features five ISO 7 cGMP cleanroom suites. The core team from Excellos will be retained to ensure continuity of existing customer programs. OrganaBio's expanded platform now spans multiple facilities across the U.S., offering comprehensive services for cell therapy developers.
Why It's Important?
The acquisition is significant as it addresses a critical challenge in the cell therapy industry: the need for reliable and redundant manufacturing capabilities. By expanding its geographic reach and integrating Excellos' facilities, OrganaBio can offer enhanced service continuity and quality assurance to its clients, which include top global pharmaceutical companies. This move is expected to reduce supply chain risks and improve the efficiency of bringing cell therapies from development to market, ultimately benefiting patients awaiting these treatments.
What's Next?
In the coming months, OrganaBio plans to focus on operational continuity and integration of services across its expanded platform. The company aims to maintain existing operations while gradually introducing broader capabilities. Full integration is expected within the next 12 months, with an emphasis on operational speed, quality, and supporting growth across the combined customer base.
